BioCentury | May 1, 2020
Distillery Therapeutics

Blocking necroptosis to treat inflammatory bowel disease

...DISEASE CATEGORY: Autoimmune disease INDICATION: Inflammatory bowel disease (IBD) Inhibiting necroptosis by targeting RIPK3, MLKL or...
...of SETDB1 mRNA and protein, as well as lower protein levels of ZBP1 and phosphorylated MLKL...
...tissue from healthy individuals. In a mouse model of IBD induced by SETBD1 knockout, RIPK3, MLKL...
BioCentury | Sep 10, 2018
Distillery Therapeutics

Cancer

...INDICATION: Melanoma; colorectal cancer Cell culture and mouse studies suggest MLKL mRNA plus electroporation could help...
...cancer. In a mouse melanoma cell line and three human melanoma cell lines, transfection with MLKL...
...other methods of delivering MLKL mRNA in animal models of melanoma and colorectal cancer. TARGET/MARKER/PATHWAY: Mixed-lineage kinase domain-like (MLKL)...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Infectious disease

...could include optimizing and testing necrosulfamide in additional models of sepsis. TARGET/MARKER/PATHWAY: Gasdermin D (GSDMD); mixed-lineage kinase domain-like (MLKL)...
BioCentury | Aug 31, 2017
Targets & Mechanisms

Necroptosis strikes again

...PRODUCT PROFILE BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Small molecule MLKL inhibitor Concept Inhibition of MLKL...
...aggregates. Oddo's team analyzed RIPK1, RIPK3, and MLKL expression in brains and found RIPK1 and MLKL...
...increased in the AD brains although binding of RIPK3 to RIPK1 and MLKL did increase. MLKL...
BioCentury | Dec 13, 2016
Distillery Therapeutics

Cancer

...culture and mouse studies suggest combining Ridaura auranofin and glutathione synthesis inhibitors with RIPK1 or MLKL...
...with Ridaura and the glutathione synthesis inhibitor, co-treatment with inhibitor tool compounds against RIPK1 or MLKL...
...TARGET/MARKER/PATHWAY: Tuberous sclerosis complex tumor suppressor 1 (TSC1); TSC2; receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1); mixed-lineage kinase domain-like (MLKL)...
BioCentury | Nov 9, 2016
Distillery Therapeutics

Hepatic

...inhibiting MLKL could help treat autoimmune hepatitis. In patients with autoimmune hepatitis, liver levels of MLKL...
...MLKL expression. Next steps could include identifying and testing MLKL inhibitors in the model. TARGET/MARKER/PATHWAY: Mixed-lineage kinase domain-like (MLKL)...
...17, 2016 doi:10.1172/JCI87545 CONTACT: Stefan Wirtz, University of Erlangen-Nuremberg, Erlangen, Germany email: stefan.wirtz@uk-erlangen.de Esme Gaisford University of Erlangen-Nuremberg Mixed-lineage kinase domain-like (MLKL)...
BioCentury | Aug 4, 2016
Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1); RIPK3 (RIP3); mixed-lineage kinase domain-like (MLKL)

...necroptosis-related proteins RIPK1 , RIPK3 or MLKL could help treat atherosclerosis. Levels of RIPK3 and MLKL...
...the number of atherosclerotic lesions, the necrotic core area of plaques and levels of phosphorylated MLKL...
...marker of plaque stability - compared with vehicle. Next steps include evaluating RIPK1, RIPK3 and/or MLKL...
BioCentury | Mar 3, 2016
Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); mixed-lineage kinase domain-like (MLKL)

...Renal disease INDICATION: Renal damage Cell and mouse studies suggest inhibiting RIPK3 or MLKL could help...
...treat crystal-induced acute kidney injury (AKI). In mouse kidney epithelial cells, siRNA targeting RIPK3 or MLKL...
...exposed to any of the crystals, pretreatment with an RIPK3 inhibitor and pretreatment with an MLKL...
Items per page:
1 - 8 of 8